Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Growth in Short Interest

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 1,500 shares, a growth of 200.0% from the September 30th total of 500 shares. Based on an average trading volume of 1,300 shares, the short-interest ratio is currently 1.2 days.

Clinuvel Pharmaceuticals Stock Up 5.3 %

OTCMKTS:CLVLY traded up $0.47 during trading hours on Friday, hitting $9.32. The stock had a trading volume of 112 shares, compared to its average volume of 2,761. The business’s 50 day moving average is $9.65 and its 200-day moving average is $9.81. Clinuvel Pharmaceuticals has a one year low of $8.42 and a one year high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a $0.0299 dividend. This is a boost from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date was Monday, September 9th.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).